Meritage Portfolio Management Has $785,000 Position in Bristol-Myers Squibb (NYSE:BMY)

Meritage Portfolio Management decreased its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 77.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,294 shares of the biopharmaceutical company's stock after selling 53,868 shares during the quarter. Meritage Portfolio Management's holdings in Bristol-Myers Squibb were worth $785,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. raised its position in shares of Bristol-Myers Squibb by 6.8% in the 3rd quarter. GHP Investment Advisors Inc. now owns 6,076 shares of the biopharmaceutical company's stock valued at $343,000 after purchasing an additional 386 shares in the last quarter. Boston Trust Walden Corp raised its position in shares of Bristol-Myers Squibb by 5.3% during the 3rd quarter. Boston Trust Walden Corp now owns 15,258 shares of the biopharmaceutical company's stock valued at $886,000 after acquiring an additional 771 shares in the last quarter. Strategic Blueprint LLC raised its position in shares of Bristol-Myers Squibb by 8.6% during the 3rd quarter. Strategic Blueprint LLC now owns 5,440 shares of the biopharmaceutical company's stock valued at $316,000 after acquiring an additional 431 shares in the last quarter. Kempner Capital Management Inc. acquired a new stake in shares of Bristol-Myers Squibb during the 3rd quarter valued at approximately $2,844,000. Finally, Aaron Wealth Advisors LLC raised its position in shares of Bristol-Myers Squibb by 30.9% during the 3rd quarter. Aaron Wealth Advisors LLC now owns 134,081 shares of the biopharmaceutical company's stock valued at $7,782,000 after acquiring an additional 31,622 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Price Performance

BMY stock traded up $0.16 during trading hours on Friday, hitting $44.86. 21,279,666 shares of the stock traded hands, compared to its average volume of 15,968,238. The stock has a 50-day simple moving average of $51.03 and a 200 day simple moving average of $51.18. Bristol-Myers Squibb has a one year low of $44.34 and a one year high of $69.10. The company has a market cap of $90.92 billion, a P/E ratio of 11.62, a P/E/G ratio of 1.47 and a beta of 0.39. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The business had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the prior year, the business posted $2.05 earnings per share. Bristol-Myers Squibb's revenue was up 4.7% compared to the same quarter last year. Equities analysts forecast that Bristol-Myers Squibb will post 6.63 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 5.35%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently 62.18%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BMY. Societe Generale lowered Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a research report on Monday, March 11th. StockNews.com downgraded Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Monday, April 15th. Wells Fargo & Company upped their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an "equal weight" rating in a research note on Thursday, April 18th. Barclays lowered their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an "equal weight" rating for the company in a research note on Friday. Finally, BMO Capital Markets lowered their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a "market perform" rating for the company in a research note on Friday. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $60.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.